When: Close below $1,147 on >4M shares (failed-reclaim confirmed) OR close below $1,000 (structural break)

Then: Triggers trim framework; downgrade to Underweight

When: Close below $1,000

Then: Full exit of position; this is where medium-term trend actually breaks

Hold core position; add only at staged zones (1,070-1,090 and 1,020-1,040); honor 1,000 stop loss; maintain discipline over aggressive deployment

• MACD rolled from plus 21.81 to minus 0.78 in seven trading days; histogram at minus 9.98 and expanding negative
• ATR at 38 points indicates momentum-accelerating selloff, not gentle drift
• Stock dropped 120 points in 10 sessions; failed to reclaim 50 SMA on two consecutive sessions
• Market is forward-looking; stock at $1,160 versus 52-week high of $1,292 signals changed risk-adjusted outlook
• Valuation at 24.5x forward earnings on 30% growth assumes growth materializes; slippage to 20% compresses multiple
• Receivables up 70% year-over-year to $23.5B suggests possible channel stuffing or revenue recognition risk
• Inventory up 4x against 2.8x revenue growth creates working capital drag and potential write-down risk
• Goodwill more than doubled from roughly $12B to $27B in 24 months via ten acquisitions; integration risk is massive
• $2.875B Merida deal has Phase I lead asset with approximately 90% historical failure probability
• Polymarket pricing retatrutide FDA approval in 2026 at only 3% does not justify additional capital deployment
• No Fed cuts priced at 89%; elevated discount rate structurally pressures long-duration growth name at 24.5x
• 200 SMA support zone at 1,058; 1,000 stop loss appropriately placed below with room to breathe
• Staged entry plan accepts missing 5-10% upside to avoid 15% drawdown risk; that is capital preservation, not paralysis
• Hedging provides insurance value precisely because outcomes cannot be predicted; not negative expected value

→ vs aggressive: Retail silence does not prove stealth accumulation; institutional flow could be distribution to quieter buyer base rather than accumulation

→ vs aggressive: Receivables up 70% to $23.5B is framed as 'launch ramp' but may indicate aggressive channel stuffing, extended payment terms, or revenue recognition risk requiring scrutiny

→ vs aggressive: Inventory up 4x versus 2.8x revenue growth growing faster than sales creates write-down risk if demand slows; not just 'safety stock'

→ vs aggressive: $2.875B Merida deal with Phase I asset at 90% failure probability is not asymmetric upside; it is high binary risk that could trigger goodwill write-down

→ vs aggressive: Polymarket 3% approval probability for retatrutide reflects correct development timeline assessment; speculative optionality not a reason to chase

→ vs aggressive: Elevated discount rates at 89% no Fed cuts creates structural multiple headwind for long-duration growth name; macro is not neutral tailwind

→ vs aggressive: Calling discipline 'paralysis' is rhetorical trick that convinces investors to catch falling knife; staged plan is high-conviction risk-managed structure

→ vs aggressive: Valuation assumes favorable resolution of all uncertain outcomes; PEG of 1.12 requires smooth execution that is not guaranteed

→ vs aggressive: Hedging framed as 'negative expected value' assumes knowledge of expected path; we do not know future outcomes

HOLD with staged adds at 1,070–1,090 and 1,020–1,040; widen stop to 980; add 25% tactical put spread hedge costing 1–2% of position

• Fundamentals are extraordinary: 30% revenue growth, 54% operating margins, 102% ROE, 24.5x forward P/E
• Retatrutide priced at 3% for 2026 approval is realistic timeline, not mispricing—already in the multiple
• 70% receivables increase on 30% revenue growth is a real flag warranting monitoring, not dismissible as unambiguously bullish
• Merida Phase I asset framed as thesis-changer is overreach; 10 acquisitions in a year creates integration risk
• Technical setup is broken: price below 10 EMA and 50 SMA, MACD rolling negative, histogram expanding bearish
• Waiting for 1,058 (200 SMA) is not a free option—catalysts may hit before that level
• Original stop at 1,000 is too tight given 38-point ATR; single session can move 30–40 points; widens to 980
• Hedging is not cheap insurance for low-beta names; LLY beta is 0.51; full hedging framework drags on returns
• Modified plan: widen stop to 980, add 25% tactical put spread hedge costing 1–2% of position value against break below 200 SMA

→ vs aggressive: Retatrutide 3% approval probability is not a near-term catalyst justification; fundamentals already priced into 24.5x forward P/E

→ vs aggressive: Calling all balance sheet signals unambiguously bullish is motivated reasoning; receivables up 70% is a real flag

→ vs aggressive: Framing Phase I Merida asset as thesis-changer loses track of how much is paid today for optionality

→ vs conservative: Waiting for 1,058 is not a free option—positive catalysts may hit before the stock reaches that level

→ vs conservative: Stop at 1,000 is too tight for a stock with 38-point ATR; normal volatility could trigger exit right before bounce

→ vs conservative: Hedging is not cheap insurance on a 0.51 beta name; protective puts are expensive relative to actual downside